Literature DB >> 7786005

Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections.

J Alder1, J Clement, J Meulbroek, N Shipkowitz, M Mitten, K Jarvis, A Oleksijew, T Hutch, L Paige, B Flamm.   

Abstract

The 2-pyridones are a new class of broad-spectrum orally bioavailable antibacterial agents. These compounds are potent bacterial DNA gyrase inhibitors which differ from fluoroquinolones by placement of the nitrogen atom in the ring juncture. ABT-719 is an S isomer and a representative 2-pyridone. ABT-719 administered orally or subcutaneously was 4- to 10-fold more effective than ciprofloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes infections in normal mice. ABT-719 was equivalent in efficacy to ciprofloxacin for treatment of gram-negative bacterial infections caused by Pseudomonas aeruginosa or Escherichia coli. The racemate and R forms of ABT-719 produced similar results against gram-positive and gram-negative bacterial infections. The 50% effective doses of ABT-719 were at least threefold lower than those of ciprofloxacin for therapy of intracellular infections caused by Salmonella typhimurium or Listeria monocytogenes. In immunosuppressed mice, ABT-719 was more effective than ciprofloxacin against quinolone-sensitive S. aureus, Enterococcus faecalis, and Enterococcus faecium. The pharmacokinetic properties of ABT-719 were consistent with its relative efficacy. The 2-pyridones are potent, orally available antibacterial agents with efficacy against gram-positive and gram-negative bacterial infections in mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786005      PMCID: PMC162663          DOI: 10.1128/AAC.39.4.971

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Fluoroquinolone antimicrobial agents.

Authors:  D C Hooper; J S Wolfson
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

3.  Emerging resistance to fluoroquinolones in staphylococci: an alert.

Authors:  M Trucksis; D C Hooper; J S Wolfson
Journal:  Ann Intern Med       Date:  1991-03-01       Impact factor: 25.391

4.  Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis.

Authors:  L O Gentry; G G Rodriguez
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

5.  Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.

Authors:  A L Barry; P C Fuchs
Journal:  J Antimicrob Chemother       Date:  1991-11       Impact factor: 5.790

6.  Clinical use of the quinolones.

Authors:  H C Neu
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

Review 7.  Quinolones in the treatment of lower respiratory tract infections.

Authors:  J P Thys; F Jacobs; S Motte
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

8.  beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis.

Authors:  M Ingerman; P G Pitsakis; A Rosenberg; M T Hessen; E Abrutyn; B E Murray; M E Levison
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

9.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

10.  In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.

Authors:  J J Clement; S K Tanaka; J Alder; C Vojtko; J Beyer; D Hensey; N Ramer; D McDaniel; D T Chu
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more
  3 in total

1.  Efficacies of ABT-773, a new ketolide, against experimental bacterial infections.

Authors:  M J Mitten; J Meulbroek; M Nukkala; L Paige; K Jarvis; A Oleksijew; A Tovcimak; L Hernandez; J D Alder; P Ewing; Y S Or; Z Ma; A M Nilius; K Mollison; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

2.  Protective effect of Qnr on agents other than quinolones that target DNA gyrase.

Authors:  George A Jacoby; Marian A Corcoran; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

3.  In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains.

Authors:  A Oleksijew; J Meulbroek; P Ewing; K Jarvis; M Mitten; L Paige; A Tovcimak; M Nukkula; D Chu; J D Alder
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.